Compounds > r-120758
Page last updated: 2024-11-11

r-120758

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

R-120758: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6475890
CHEMBL ID475786
SCHEMBL ID2927807
SCHEMBL ID2927804
SCHEMBL ID2927801
SCHEMBL ID4681178
MeSH IDM0422616

Synonyms (23)

Synonym
4-[(1e,3e)-4-[5-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]sulfanyl-1,3-dioxan-2-yl]buta-1,3-dienyl]-3-fluoro-benzonitrile
cs-758, r-120758
benzonitrile, 4-[(1e,3e)-4-[5-[[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]-1,3-butadienyl]-3-fluoro-
embeconazole
r-120758
cs-758
CHEMBL475786
4-[(1e,3e)-4-[5-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]sulfanyl-1,3-dioxan-2-yl]buta-1,3-dienyl]-3-fluorobenzonitrile
329744-44-7
02b953tlai ,
4-((1e,3e)-4-(trans-5-(((2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1h-1,2,4-triazol-1-yl)butan-2-yl)sulfanyl)-1,3-dioxan-2-yl)buta-1,3-dien-1-yl)-3-fluorobenzonitrile
unii-02b953tlai
embeconazole [inn]
SCHEMBL2927807
SCHEMBL2927804
SCHEMBL2927801
4-((1e,3e)-4-(trans-5-(((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)thio)-1,3-dioxan-2-yl)-1,3-butadienyl)-3-fluorobenzonitrile
XSRKBFUVSRRJDX-GGZJQHSXSA-N
(2r,3r)-3-[[trans-2-[(1e,3e)-4-(4-cyano-2-fluorophenyl)-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)-2-butanol
(2r,3r)-3-[[trans-2-[(1e,3e)-4-(4-cyano-2-fluorophenyl)-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-(2,4-difluorophenyl)-1-(1-h-1,2,4-triazol-1-yl)-2-butanol
4-[(1e,3e)-4-[trans-5-[[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]-1,3-butadienyl]-3-fluorobenzonitrile
SCHEMBL4681178
Q27231514

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" It was also converted to CS-758 in rats after iv administration, wherein the bioavailability of CS-758 was 53%."( Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758.
Iida, T; Kagoshima, Y; Kamai, Y; Konosu, T; Mori, M; Shibayama, T; Suzuki, E, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1872519Antifungal activity against Candida albicans SANK 51486 by 96-well microplate method2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID419074Antifungal activity against Candida tropicalis ATCC 7502009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419079Antifungal activity against Candida albicans ATCC 645502009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419071Antifungal activity against Candida albicans SANK 514862009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419084Bioavailability in rat at 20 mg/kg, po2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419073Antifungal activity against Candida glabrata ATCC 900302009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID1872521Antifungal activity against Aspergillus fumigatus SANK 10569 by 96-well microplate method2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872538Antifungal activity against Aspergillus2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID371862Bioavailability in rat at 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758.
AID1872520Antifungal activity against Cryptococcus neoformans TIMM 1855 by 96-well microplate method2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID419075Antifungal activity against Cryptococcus neoformans TIMM 18552009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419077Antifungal activity against Aspergillus flavus SANK 184972009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419081Antifungal activity against Candida krusei ATCC 62582009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419078Antifungal activity against Candida albicans ATCC 244332009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID371864Antifungal activity against Candida albicans SANK 51486 infected in mouse at 0.2 to 20 mg/kg, iv administered 2 hrs post infection measured after 24 hrs2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758.
AID419072Antifungal activity against fluconazole-resistant Candida albicans TIMM31642009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID371863Cmax in rat at 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Synthesis, cleavage, and antifungal activity of a number of novel, water-soluble ester prodrugs of antifungal triazole CS-758.
AID419080Antifungal activity against Candida parapsilosis ATCC 900182009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID1872522Antifungal activity against Aspergillus flavus SANK 18497 by 96-well microplate method2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID419076Antifungal activity against Aspergillus fumigatus SANK 105692009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419082Antifungal activity against Aspergillus fumigatus ATCC 264302009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
AID419083Chemical stability assessed as half life in HCl2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Amide analogs of antifungal dioxane-triazole derivatives: synthesis and in vitro activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.22 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (30.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		4.0640conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
itraconazole
[no description available]		3.6220piperazines
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		210aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		5.14801,2,3-triazole
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		3.5110cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
ravuconazole
ER 30346: structure in first source. ravuconazole : A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4)		3.51101,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles		antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor
micafungin
Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.		3.1110antibiotic antifungal drug;
echinocandin		antiinfective agent
efinaconazole
efinaconazole: an antifungal agent; structure in first source. efinaconazole : A member of the class of triazoles that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,4-difluorophenyl, and 4-methylenepiperidin-1-yl groups, respectively (the 2R,3R stereoisomer). It is an antifungal drug used for the topical treatment of onychomycosis (a nail infection caused mainly by dermatophytes).		3.5110conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
tak 456
TAK 456: structure in first source		3.5110
2-(2,4-difluorophenyl)-3-(4-(4-(2-(4-trifluoromethoxybenzyl)-2h-1,2,4-triazol-3-one-4-yl)phenyl)piperazin-1-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
Syn 2869: structure in first source		3.5110
isavuconazole
isavuconazole : A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis.		3.51101,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug		EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug
r-106
[no description available]		3.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Candida Infection
[description not available]		02.7330
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.7330
Aspergillus Infection
[description not available]		02.0510
Fungal Diseases
[description not available]		02.4320
Aspergillosis
Infections with fungi of the genus ASPERGILLUS.		02.0510
Mycoses
Diseases caused by FUNGI.		02.4320
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0110